OpenBilldrug price receipt

NADAC week of 2026-10-14

LINZESS 145 MCG CAPSULE

FDA nonproprietary name: linaclotide

For 30 capsules

Pharmacies pay

$270.60 filed

30 × $9.01992 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$530.57 filed

30 × $17.6855 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

2.0× estimated

Medicare paid 2.0× what pharmacies pay.

Part D averages every strength and form sold under “Linzess” / “Linaclotide” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$316.19 estimated

$270.60 + $40.59 (15%) + $5.00 fee per fill = $316.19

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

LINZESS 145 MCG CAPSULE is how the CMS NADAC file names this product. The FDA NDC Directory lists it as linaclotide, under the trade name “Linzess”.

FDA gives its dosage form as capsule, gelatin coated and its route as oral.

The labeler, the company named on the label, is Allergan, Inc.

FDA’s Established Pharmacologic Class for it is Guanylate Cyclase-C Agonist.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 00456-1201-30.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $270.60 for 30 capsules (30 × $9.01992 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

The NDC

Other strengths, forms and brands

2 other products in the NADAC file share the FDA nonproprietary name linaclotide with LINZESS 145 MCG CAPSULE.

ProductPharmacies pay per unitMedicare per unit
LINZESS 72 MCG CAPSULE
brand · capsule, gelatin coated
$9.01079 per EA filed
eff. 2026-09-23
$17.6855 per EA filed
Part D 2024 average
LINZESS 145 MCG CAPSULE this page
brand · capsule, gelatin coated
$9.01992 per EA filed
eff. 2026-09-23
$17.6855 per EA filed
Part D 2024 average
LINZESS 290 MCG CAPSULE
brand · capsule, gelatin coated
$9.01543 per EA filed
eff. 2026-09-23
$17.6855 per EA filed
Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

What Medicare paid

Medicare Part D paid $530.57 for 30 capsules, at an average of $17.6855 per EA in 2024 (2024-01-01 to 2024-12-31) for “Linzess” and “Linaclotide”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 2,506,531 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for LINZESS 145 MCG CAPSULE labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Linzess / Linaclotide: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.